INDV - CIK 0001625297
INDIVIOR PLC trades as INDV and has a market capitalization of $4.64 B, making it the #1456 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.24B, up 4.3% from the prior year and net income of $210.00M. This page tracks INDIVIOR PLC through 513 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -4.7% to 16.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.
2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd
Under the ASR agreement, Indivior will make an upfront payment of $175 million to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly following execution. The final number of shares repurchased will be determined based on the volume weighted average price of Indivior’s common stock during the term of the ASR, less a discount. Final settlement is expected to occur no later than the end of June 2026. Indivior does not expect the ASR to impact its previously issued financial guidance.
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY
The largest companies sharing INDIVIOR PLC's SEC industry classification (pharmaceutical preparations).
INDIVIOR PLC (INDV) has a market capitalization of $4.64 B as of 2026-06-10, ranking #1456 among US-listed companies.
INDIVIOR PLC reported revenue of $1.24B for fiscal year 2025, an increase of 4.3% year over year.
Yes. INDIVIOR PLC reported net income of $210.00M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder